Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

Original reporting
Published Nov 20, 2026, 12:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 12:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$REGN
Bullish
high confidence
Mentioned
$REGN
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$REGNBullishHigh
01

Why it matters

The combined regulatory and analyst actions create a fresh bullish catalyst for REGN.

02

Market read

Regeneron's stock is likely to rally on the day of the FDA approval and analyst upgrades.

03

What to watch

Potential pricing pressure from competing therapies and reimbursement uncertainties.

Relevance 7/10Novelty 8/10Timing: immediate

Background

Regeneron reported strong Q3 sales driven by Dupixent and announced FDA approval for Livsayis, while analysts raised price targets.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

Argus raised its price target to $1,050 and FDA approved Regeneron's Livsayis, indicating fresh positive catalyst.

Expected impact

likely upward pressure as the market prices in the approval and upgraded targets

Evidence & confidence

New regulatory approval and multiple analyst upgrades provide fresh, material information that can move the stock immediately.

Market effects

Biopharma sector may see broader optimism for antibody therapeutics after the approval.

US biotech indices could gain modestly.

Limited to investors tracking US-listed biotech stocks.

Counterpoint

If the approval faces post-market safety concerns, the rally could be short-lived.

Key entities

  • Regeneron Pharmaceuticals

    US-listed biopharma developing antibody therapies.

  • Argus Research

    Equity research firm that raised REGN price target.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.

$REGNMed

REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals received FDA approval for Livsayis, a siRNA therapy for generalized myasthenia gravis (gMG). It is the first of its kind and is administered subcutaneously four times a year. The approval was based on positive phase III NIMBLE study results, showing significant symptom improvement. Livsayis carries a Boxed Warning for serious infections. Regeneron's stock has risen 22.9% year-to-date. The therapy is under review in the EU and planned for other regions.